- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07579585
Effects of Photobiomodulation in Hemophilia Patients.
Effects of Photobiomodulation on Knee Hemarthosis in Patients With Hemophilia.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Imran Amjad, Phd
- Phone Number: 03324390125
- Email: imran.amjad@riphah.edu.pk
Study Contact Backup
- Name: Muhammad Asif Javed, PhD*
- Phone Number: +923224209422
- Email: a.javed@riphah.edu.pk
Study Locations
-
-
Punjab Province
-
Sialkot, Punjab Province, Pakistan, 5100
- Recruiting
- Sundas Foundation
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Hemophilia patients with knee hemarthosis
- Patients of age 9-14 yrs will be taken
- Bothmaleand female population will be included
Exclusion Criteria:
- Presence of open wounds at or near the treatment site.
- Kneejoint subluxation.
- Presence of congenital or acquired skeletal deformities.
- Children diagnosed with cardiopulmonary dysfunctions.
- Children with neurological deficits
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: photobiomodulation
The intervention involves the application of low-level laser therapy (LLLT), also referred to as photobiomodulation (PBM), using a diode laser device with the intensity in the range of 1 to 500 mW .
The laser was applied in continuous-wave mode directly to the skin over the knee joint at multiple anatomical points, including the medial, lateral, superior, and inferior aspects of the patella, covering 8 to 9 specific locations.
Total treatment time will be 10 minutes, delivered with a spot size 13 Effects of Photobiomodulation o knee hemarthosis in children with Hemophilia ranging from 0.04 to 0.07 cm².
During the procedure, patients are positioned in a supine posture with the knee slightly flexed (20-30°) to allow optimal access to the target areas.
|
Photobiomodulation is a non-invasive therapy that uses low-level light (typically from lasers or LEDs) to stimulate cellular activity and promote healing.
It works by enhancing mitochondrial function, increasing energy (ATP) production, and reducing inflammation.
This therapy is commonly used for pain relief, tissue repair, and improving recovery in various clinical conditions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
VAS
Time Frame: 3rd Day
|
The Visual Analogue Scale (VAS) is a simple and widely used tool to measure a person's pain intensity. It typically consists of a 10 cm straight line, where: One end represents "no pain" (0) The other end represents "worst possible pain" (10) The patient is asked to mark a point on the line that best represents their level of pain. The distance from the "no pain" end to the marked point is then measured and recorded as the pain score. VAS is easy to use, quick, and effective for tracking changes in pain over time in both clinical and research settings. |
3rd Day
|
|
Measuring Tape
Time Frame: 3rd Day
|
A measuring tape in physiotherapy is a simple, flexible tool used to assess body dimensions such as limb length, girth, and joint swelling.
It helps therapists monitor changes over time, evaluate muscle atrophy or edema, and track patient progress during rehabilitation.
|
3rd Day
|
|
Goniometer
Time Frame: 3rd Day
|
A goniometer is a scientific instrument used to measure angles.
It is commonly used in fields like geometry, engineering, and healthcare.
In medicine-especially in physical therapy and orthopedics-it helps measure the range of motion of joints in the human body.
A typical goniometer consists of a protractor-like scale with two arms that can be aligned along the body part or object to determine the angle accurately.
|
3rd Day
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Zaira Zeeshan, MS, Riphah International University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Musculoskeletal Diseases
- Pathologic Processes
- Joint Diseases
- Genetic Diseases, Inborn
- Hemorrhage
- Hematologic Diseases
- Blood Coagulation Disorders
- Hemorrhagic Disorders
- Blood Coagulation Disorders, Inherited
- Coagulation Protein Disorders
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Pathological Conditions, Signs and Symptoms
- Hemic and Lymphatic Diseases
- Hemophilia A
- Hemarthrosis
- Therapeutics
- Laser Therapy
- Phototherapy
- Low-Level Light Therapy
Other Study ID Numbers
- Zaira Zeeshan
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemophilia
-
Nantes University HospitalCompletedArthropathy | Moderate HemophiliaFrance
-
ApcinteX LtdCentessa Pharmaceuticals plcTerminatedHemophilia B | Hemophilia a | Hemophilia a with Inhibitor | Hemophilia B with InhibitorGeorgia, Moldova, Republic of
-
Catalyst BiosciencesCompletedHemophilia A | Hemophilia B | Hemophilia A With Inhibitor | Hemophilia B With Inhibitor | Hemophilia A Without Inhibitor | Hemophilia B Without InhibitorBulgaria, Russian Federation
-
BayerCompletedHemophilia A; Hemophilia BIsrael
-
GWT-TUD GmbHHannover Medical School; Hoffmann-La RocheCompleted
-
PfizerCompletedFactor VIII Deficiency, Congenital | Hemophilia A, Congenital | Factor 8 Deficiency, Congenital | Autosomal Hemophilia A | Classic Hemophilia
-
Laboratoire français de Fractionnement et de BiotechnologiesLFB USA, Inc.CompletedA Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (PERSEPT2)Hemophilia A With Inhibitors | Hemophilia B With InhibitorsBulgaria, Ukraine, Czechia, United States, Georgia, South Africa
-
Catalyst BiosciencesCompletedHemophilia A With Inhibitor | Hemophilia B With InhibitorArmenia, Georgia, South Africa, Poland, Russian Federation
-
CSL BehringTerminatedHemophilia A With Inhibitors | Hemophilia B With InhibitorsGeorgia, Italy, Malaysia, Russian Federation, South Africa, Spain, Thailand, Ukraine, United Kingdom
-
University College, LondonRecruiting
Clinical Trials on photobiomodulation
-
University of Nove de JulhoNot yet recruitingPostmenopausal Symptoms
-
University of Nove de JulhoNot yet recruiting
-
University of Nove de JulhoNot yet recruiting
-
University of Nove de JulhoNot yet recruiting
-
University of Nove de JulhoUnknownTemporomandibular DisorderBrazil
-
Quietmind FoundationMaculume Ltd.Completed
-
Universidade Federal de Sao CarlosThe São Paulo Research Foundation (FAPESP)Recruiting
-
University of Nove de JulhoUnknownSoft Tissue Injuries
-
University of Nove de JulhoCompletedTemporomandibular DisordersBrazil
-
Brigham and Women's HospitalActive, not recruiting